The consequences of doxorubicin quinone reduction in vivo in tumour tissue.
AffiliationImperial Cancer Research Fund, Western General Hospital, Edinburgh, U.K.
MetadataShow full item record
AbstractA clear role for quinone reduction in the mechanism of action of doxorubicin has still to be established. There are three possible outcomes of this form of doxorubicin metabolism: (1) drug free radical formation, redox cycling and generation of reactive oxygen species (ROS) resulting in lipid peroxidation and DNA damage; (2) covalent binding of reactive drug intermediates to DNA; and (3) formation of an inactive 7-deoxyaglycone metabolite. In this work, the occurrence of each of these pathways has been studied in vivo in a subcutaneously growing rat mammary carcinoma (Sp 107). Doxorubicin was administered by direct intratumoural injection either as the free drug or incorporated in albumin microspheres (10-40 microns diameter). There was no evidence of an increase in lipid peroxidation over background after either treatment at any time point studied. In fact, doxorubicin administration resulted in a statistically significant reduction in lipid peroxidation at the later time points studied compared to control (no drug treatment), e.g. 24 hr: control, 21.7 +/- 2.8 SD nmol malondialdehyde/g tissue; free doxorubicin (70 micrograms drug), 14.5 +/- 4.0 SD nmol/g (P < 0.01 Student's t-test) and doxorubicin microspheres (70 micrograms drug), 17.4 +/- 1.1 nmol/g (P < 0.05). Covalent binding to DNA was measured by a 32P-post-labelling technique. Low levels of four putative drug-DNA adducts were detected; however, there were no qualitative or quantitative differences in profiles between free drug and microspheres. High 7-deoxyaglycone metabolite concentrations comparable to the parent drug itself were detected after administration of microspheres (3.0 micrograms/g +/- 1.7 SD at 24 hr and 3.1 micrograms/g +/- 1.1 SD at 48 hr). In contrast, these metabolites were present at levels close to the limit of detection of our HPLC assay after free drug (0.04 microgram/g +/- 0.03 SD at 24 hr and 0.02 microgram/g +/- 0.03 SD at 48 hr). Thus, 7-deoxyaglycone metabolite formation can occur in tumour tissue (indicating active drug quinone reduction) without concomitant increases in the level of lipid peroxidation or the levels of drug-DNA adducts. In conclusion, the main biological consequence of doxorubicin quinone reduction in vivo in tumour tissue would appear to be drug inactivation to a 7-deoxyaglycone metabolite rather than drug activation to DNA reactive species or ROS.
CitationThe consequences of doxorubicin quinone reduction in vivo in tumour tissue. 1992, 44 (11):2165-74 Biochem. Pharmacol.
- The enzymology of doxorubicin quinone reduction in tumour tissue.
- Authors: Cummings J, Allan L, Willmott N, Riley R, Workman P, Smyth JF
- Issue date: 1992 Dec 1
- Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activity.
- Authors: Willmott N, Cummings J, Marley E, Smyth JF
- Issue date: 1990 Mar 15
- Covalent coupling of doxorubicin in protein microspheres is a major determinant of tumour drug disposition.
- Authors: Cummings J, Willmott N, Marley E, Smyth J
- Issue date: 1991 Jun 15
- Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity. Implications for the drugs' in vivo mechanism of action.
- Authors: Cummings J, Allan L, Smyth JF
- Issue date: 1994 Apr 20
- Increased anti-tumor effect of adriamycin-loaded albumin microspheres is associated with anaerobic bioreduction of drug in tumor tissue.
- Authors: Willmott N, Cummings J
- Issue date: 1987 Feb 15